ESTA
HealthcareEstablishment Labs Holdings Inc. · Medical - Devices · $2B
What is Establishment Labs Holdings Inc.?
Establishment Labs Holdings is a medical technology company focused on aesthetic and reconstructive plastic surgery devices. Headquartered in Alajuela, Costa Rica, it markets its products across Europe, Latin America, and the Asia-Pacific region.
Establishment Labs generates revenue by manufacturing and selling silicone gel-filled breast implants under the Motiva Implants brand. The company reaches customers through a combination of exclusive distributors and a direct sales force operating across international markets. Beyond implants, it offers tissue expanders and distributes a line of products for fat harvesting and redistribution procedures, broadening its footprint in the aesthetics and reconstructive surgery space.
The company was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
- Motiva Implants silicone gel-filled breast implants
- Motiva Ergonomix and Ergonomix2 gravity-sensitive implants
- Motiva Flora Tissue Expander for breast reconstruction
- Puregraft autologous adipose tissue harvesting products
Is ESTA a Good Stock to Buy?
UQS Score rates ESTA as Below Average overall, reflecting a mixed profile where standout growth is offset by meaningful structural weaknesses.
The Growth pillar is the clearest bright spot in ESTA's profile, suggesting the company is expanding its commercial reach at a pace that stands out relative to sector peers. The Risk pillar lands at Neutral, indicating the risk profile is neither particularly alarming nor especially reassuring compared to the broader healthcare device universe.
Both the Quality and Moat pillars register as Weak, pointing to challenges in underlying business fundamentals and competitive durability. The Valuation pillar reads as Elevated, meaning the market is pricing in a great deal of future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ESTA pay dividends?
No — Establishment Labs Holdings Inc. does not currently pay a dividend.
Establishment Labs does not currently pay a dividend. For a growth-stage medical technology company expanding into new geographies and building out its product portfolio, retaining capital for reinvestment is the typical approach. Investors drawn to ESTA are generally seeking capital appreciation rather than income.
When does ESTA report earnings?
Establishment Labs reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's results have reflected the dynamics of a growth-oriented medical device business — expanding international sales alongside ongoing investment in commercial infrastructure. Revenue trends have generally moved in a positive direction, though profitability metrics remain a point of scrutiny given the Weak Quality pillar rating.
For the most recent quarter's results and guidance, visit Establishment Labs' investor relations page directly.
ESTA Price History
-19.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Establishment Labs Holdings Inc.?
Based on Establishment Labs Holdings Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ESTA Long-term Outlook
The Strong Growth pillar suggests Establishment Labs has meaningful commercial momentum in its core markets, particularly as aesthetic surgery demand continues to grow across international geographies. However, the Weak Quality and Moat pillars indicate that converting that growth into durable, high-quality earnings remains a challenge. The Elevated Valuation pillar adds another layer of consideration — the current price appears to embed optimistic assumptions about future execution.
Growth drivers
- International expansion across Europe, Latin America, and Asia-Pacific
- Growing adoption of the Motiva Implants product family in new markets
- Broadening product portfolio beyond implants into adjacent aesthetics procedures
Key risks
- Elevated valuation leaves little room for execution shortfalls
- Weak Moat pillar suggests limited pricing power and competitive differentiation
- Regulatory and reimbursement complexity across multiple international markets
ESTA vs Peers
Establishment Labs operates in a competitive medical device landscape alongside companies addressing different segments of surgical and reconstructive care.
AxoGen focuses on peripheral nerve repair technologies, serving a distinct surgical niche compared to ESTA's aesthetic implant focus.
Artivion specializes in cardiac and vascular surgery products, operating in a higher-acuity segment of the medical device market.
AdaptHealth is a home medical equipment and services provider, representing a different business model and patient-care setting than ESTA.
Frequently Asked Questions
What does Establishment Labs do?
Establishment Labs manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. Its flagship products are silicone gel-filled breast implants sold under the Motiva Implants brand. The company also offers tissue expanders and fat-transfer products, distributing through exclusive partners and a direct sales force across international markets.
Does ESTA pay dividends?
No, Establishment Labs does not currently pay a dividend. The company is in a growth phase, prioritizing reinvestment into commercial expansion and product development over returning cash to shareholders. Investors in ESTA are typically seeking growth rather than income.
When does ESTA report earnings?
Establishment Labs follows a standard quarterly earnings cadence for US-listed companies. For the precise schedule and most recent results, check the investor relations section of the company's official website.
Is ESTA a good stock to buy?
UQS Score rates ESTA as Below Average overall. The Growth pillar is strong, but the Quality and Moat pillars are both Weak, and the Valuation pillar is Elevated. That combination means investors are paying a premium for growth that has yet to translate into durable business fundamentals. The complete pillar breakdown is available to UQS Pro members.
Is ESTA overvalued?
The UQS Valuation pillar for ESTA is rated Elevated, suggesting the stock is priced above what the underlying fundamentals might typically justify. This does not predict near-term price movement, but it does indicate that expectations embedded in the current price are high relative to peers.
How does ESTA compare to its competitors?
Establishment Labs competes in the medical device space but occupies a focused niche in aesthetic breast surgery. Peers like AxoGen and Artivion address nerve repair and cardiac surgery respectively, making direct comparisons nuanced. ESTA's international distribution model and Motiva brand are its primary points of differentiation within aesthetics.
What is ESTA's market cap bracket?
Establishment Labs is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but also tends to carry greater volatility and liquidity risk compared to large- or mega-cap peers.
Who founded Establishment Labs?
Establishment Labs was incorporated in 2004. Founding and leadership history is publicly available through the company's official disclosures and investor relations materials for those seeking detailed background.
Is ESTA a long-term quality investment?
As a long-term quality indicator, UQS rates ESTA as Below Average. The Strong Growth pillar is encouraging, but Weak Quality and Moat scores suggest the business has not yet built the durable competitive advantages typically associated with long-term compounders. Sustained execution would need to improve those pillar ratings over time.
What is the main competitive advantage of Establishment Labs?
Establishment Labs centers its competitive positioning on the Motiva Implants brand, which emphasizes product innovation in silicone gel technology and a broad international distribution network. However, the UQS Moat pillar rates this advantage as Weak, indicating that competitive durability remains a work in progress relative to sector standards.
What sector does ESTA belong to?
Establishment Labs operates in the Healthcare sector, specifically within medical devices focused on aesthetic and reconstructive plastic surgery. This positions the company at the intersection of elective procedure demand and medical technology innovation, a segment sensitive to consumer spending trends and regulatory developments.
Is ESTA a growth stock or value stock?
Based on its UQS pillar profile, ESTA leans firmly toward the growth category. The Growth pillar is rated Strong, while the Valuation pillar is Elevated — a combination typical of companies where the market is pricing in future expansion rather than current earnings power.
Unlock Full ESTA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics behind each pillar
- ✓Compare ESTA against sector peers side by side
- ✓Track quality score changes over time
- ✓Get the complete analyst-style breakdown in one view
Pro Analysis
ESTA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 36.7 | 16.7 | 26.0 | 86.3 | 58.4 | 0.0 | -0.3 |
| May 7, 2026 | 37.0 | 16.7 | 26.0 | 86.3 | 58.8 | 1.4 | 0.0 |
| May 2, 2026 | 37.0 | 16.7 | 26.0 | 86.3 | 58.8 | 1.5 | 0.0 |
| Apr 19, 2026 | 37.0 | 16.7 | 26.0 | 86.3 | 58.8 | 1.6 | -0.5 |
| Apr 18, 2026 | 37.5 | 16.7 | 26.0 | 86.3 | 58.8 | 4.7 | 0.0 |
| Apr 14, 2026 | 37.5 | 16.7 | 26.0 | 86.3 | 58.8 | 5.1 | -0.3 |
| Apr 12, 2026 | 37.8 | 16.7 | 26.0 | 86.3 | 58.8 | 7.1 | -0.3 |
| Apr 5, 2026 | 38.1 | 16.7 | 26.0 | 86.3 | 58.8 | 8.7 | +0.1 |
| Apr 2, 2026 | 38.0 | 16.7 | 26.0 | 86.3 | 58.8 | 8.3 | — |
ESTA — Pillar Breakdown
Quality
— 16.7/100 (25%)Establishment Labs Holdings Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 86.3/100 (20%)Establishment Labs Holdings Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 58.4/100 (15%)Establishment Labs Holdings Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Establishment Labs Holdings Inc. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 26/100 (25%)Establishment Labs Holdings Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ESTA.
Score Composition
Financial Data
More Stock Analysis
How is the ESTA UQS Score Calculated?
The UQS (Unified Quality Score) for Establishment Labs Holdings Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Establishment Labs Holdings Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Establishment Labs Holdings Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.